Inflammatory biomarkers in Alzheimer's disease plasma.
Alzheimers Dement
; 15(6): 776-787, 2019 06.
Article
in En
| MEDLINE
| ID: mdl-31047856
ABSTRACT
INTRODUCTION:
Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.METHODS:
A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.RESULTS:
Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC 0.71).DISCUSSION:
Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Biomarkers
/
Alzheimer Disease
/
Cognitive Dysfunction
/
Inflammation
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Humans
Language:
En
Journal:
Alzheimers Dement
Year:
2019
Type:
Article
Affiliation country:
United kingdom